Australia markets closed

Alpine Immune Sciences, Inc. (34LA.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
59.000.00 (0.00%)
As of 03:29PM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 4.10B
Enterprise value 3.83B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)61.42
Price/book (mrq)13.23
Enterprise value/revenue 73.61
Enterprise value/EBITDA -2.59

Trading information

Stock price history

Beta (5Y monthly) 0.97
52-week change 3517.80%
S&P500 52-week change 329.31%
52-week high 361.00
52-week low 37.95
50-day moving average 348.44
200-day moving average 324.08

Share statistics

Avg vol (3-month) 332
Avg vol (10-day) 3N/A
Shares outstanding 568.6M
Implied shares outstanding 669.47M
Float 847.88M
% held by insiders 14.65%
% held by institutions 199.47%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:4
Last split date 325 July 2017

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -65.17%
Operating margin (ttm)-322.75%

Management effectiveness

Return on assets (ttm)-10.10%
Return on equity (ttm)-14.67%

Income statement

Revenue (ttm)56.52M
Revenue per share (ttm)1.04
Quarterly revenue growth (yoy)-25.10%
Gross profit (ttm)N/A
EBITDA -50.77M
Net income avi to common (ttm)-36.84M
Diluted EPS (ttm)-0.59
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)305.66M
Total cash per share (mrq)4.46
Total debt (mrq)9.65M
Total debt/equity (mrq)2.90%
Current ratio (mrq)9.56
Book value per share (mrq)5.07

Cash flow statement

Operating cash flow (ttm)-80.55M
Levered free cash flow (ttm)-41.41M